An ever increasing number of medical devices are being connected to hospital information networks via various types of connection (4G, Wi-Fi, Bluetooth and Ethernet). At the same time, more and more cases of issues associated with hacking, piracy and even theft of personal medical data are being reported in the media.
It is therefore appropriate to examine the current regulatory position vis-à-vis connected medical devices.
With the entry into force of the Medical Device (MDR) and In Vitro Diagnostic Regulations (IVDR) on May the 25th, 2017, new requirements impacting Post Market Surveillance (PMS) have raised interrogations amongst Medical Device Manufacturers.
While a continuous evaluation and improvement of the process is at the very heart of this change, the Regulations introduces more incisive and prescriptive measures based on device risk level for both the MDR and IVDR.
The Post Market Surveillance requirements are pretty similar for both the Medical Device Regulation (MDR) and the In-Vitro Diagnostic Regulation (IVDR) and are located in Chapter 7 of both regulations. Chapter 7 points out to specific Annexes describing more in detail the provisions relating to this topic.
The European Regulations on Medical Devices including Active Implantable Medical Devices (AIMD), and In Vitro Diagnostic (IVD) Medical Devices have been officially published on May 5th, 2017. Both entered into force on May the 25th, 2017.
The ISO 13485 standard represents a Quality Management System base for many regulatory schemes.
With the recent publication of the new Medical Device and In Vitro Diagnostic Regulations, the regulatory framework surrounding Medical Devices evolves and re-enforces the control of external parties (Suppliers, Subcontractors).
The newest revision of the ISO 13485 standard published in March 2016 aims in the very same direction.
The Medical Device Regulation (MDR) and the In Vitro Diagnostics Regulation (IVDR) were initially proposed in 2008 when the EU Commission triggered a consultation on the community’s existing requirements covering medical devices. The plan was 1st released by the commission in 2012 to modify the EU’s medical device regulatory framework along with a proposed regulation replacing the EU’s current Medical Device Directive 93/42/EEC, the EU’s directive on Active Implantable Medical Device 90/385/EEC, and the In Vitro Diagnostic Directive 98/79/EEC.
Within the last few years, the Medical Device industry has witnessed a series of changes. The last one took place on April 5th, when the EU Parliament concluded years of tractions and discussions with the vote of the Medical Device and In Vitro Diagnostic Regulations.